Redmile Group LLC Reduces Stake in Astria Therapeutics, Inc. $ATXS

Key Points

• Redmile Group LLC reduced its stake in Astria Therapeutics by 22.3%, now owning approximately $1.44 million worth of shares.
• Astria Therapeutics has a strong institutional backing, with 98.98% of its stock owned by institutional investors and hedge funds.
• Analysts have a generally positive outlook for Astria Therapeutics, with an average "Buy" rating and a target price of $29.00.

Redmile Group LLC reduced its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 22.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 269,078 shares of the biotechnology company's stock after selling 77,200 shares during the quarter. Redmile Group LLC owned 0.48% of Astria Therapeutics worth $1,437,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Deutsche Bank AG raised its position in shares of Astria Therapeutics by 54.3% during the fourth quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company's stock worth $355,000 after acquiring an additional 13,986 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Astria Therapeutics by 13.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company's stock worth $567,000 after purchasing an additional 7,756 shares during the period. GAMMA Investing LLC grew its stake in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,971 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Astria Therapeutics by 19.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock worth $159,000 after purchasing an additional 2,878 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in Astria Therapeutics during the fourth quarter worth approximately $50,000. 98.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. JMP Securities raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 13th. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $29.00.

Astria Therapeutics Stock Up 7.4%

Astria Therapeutics stock traded up $0.52 during mid-day trading on Friday, reaching $7.52. 542,624 shares of the company's stock were exchanged, compared to its average volume of 271,053. The business's fifty day simple moving average is $6.50 and its 200 day simple moving average is $5.70. The firm has a market capitalization of $424.43 million, a PE ratio of -3.74 and a beta of 0.42. Astria Therapeutics, Inc. has a one year low of $3.56 and a one year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. On average, sell-side analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.